No. 40100

|  |  |  |
| --- | --- | --- |
| September 29, 2022 |  | Le 29 septembre 2022 |
|  |  |  |
| BETWEEN:  Pharmascience Inc.  Applicant  - and -  Teva Canada Innovation, Teva Canada Limited and Yeda Research and Development Co., Ltd  Respondents  AND BETWEEN:  Pharmascience Inc.  Applicant  - and -  Teva Canada Innovation, Teva Canada Limited and Yeda Research and Development Co., Ltd  Respondents  AND BETWEEN:  Pharmascience Inc.  Applicant  - and -  Teva Canada Innovation, Teva Canada Limited and Yeda Research and Development Co., Ltd  Respondents |  | ENTRE :  Pharmascience Inc.  Demanderesse  - et -  Teva Canada Innovation, Teva Canada Limited et Yeda Research and Development Co., Ltd  Intimées  ET ENTRE :  Pharmascience Inc.  Demanderesse  - et -  Teva Canada Innovation, Teva Canada Limited et Yeda Research and Development Co., Ltd  Intimées  ET ENTRE :  Pharmascience Inc.  Demanderesse  - et -  Teva Canada Innovation, Teva Canada Limited et Yeda Research and Development Co., Ltd  Intimées |
|  |  |  |
| JUDGMENT  The motion to join three Federal Court of Appeal files in a single application for leave to appeal is granted. The application for leave to appeal from the judgment of the Federal Court of Appeal, Numbers A-315-20, A-316-20 and A-4-21, 2022 FCA 2, dated January 6, 2022, is dismissed with costs. |  | JUGEMENT  La requête pour joindre trois dossiers de la Cour d’appel fédérale dans une seule demande d’autorisation d’appel est accueillie. La demande d’autorisation d’appel de l’arrêt de la Cour d’appel fédérale, numéros A-315-20, A-316-20 et A-4-21, 2022 FCA 2, daté du 6 janvier 2022, est rejetée avec dépens. |

J.S.C.C.

J.C.S.C.